

# People

## Shapiro joins Idun Pharmaceuticals

David Shapiro has been appointed to the position of Executive Vice-President and Chief Medical Officer of Idun Pharmaceuticals (San Diego, CA, USA). His new role will involve overseeing drug development as well as the design and management of clinical trial programs within the company.

Shapiro comes to the job from managing the consulting company, Integrated Quality Resources. In 1995, he established the Medical Research Center at Scripps Clinic (San Diego) and will remain a Senior Consultant at the clinic. He has also previously been head of the hypertension clinical research group at Merck Research Laboratories, and Vice-President and member of the Board of Trustees and Executive Committee of the American Academy of Pharmaceutical Physicians.

## New Senior VP, Business Development at HGS

Human Genome Sciences (HGS; Rockville, MD, USA) has appointed Ellen S. Baron to the position of Senior Vice-President of Business Development where she will report to the Chairman and CEO, William Haseltine. She will be taking over the position from Arthur M. Mandell who has recently resigned from the company to become President and CEO of Stemron Corporation, a new biotech start-up company in Maryland.

Baron's previous experience in the pharmaceutical industry includes roles such as Senior Director of Business Development/Biotechnology at Schering-Plough Corporation (Kenilworth, NJ, USA) and 12 years of experience within the R&D department at Schering-Plough in positions such as Director of Biotechnology, Microbial Development, Fermentation Process Development and Cell Culture.

Craig Rosen, Executive Vice-President of R&D said: 'HGS has the opportunity to use its rich understanding of human genes and their function as a basis for creating new partnerships in drug development and commercialization. I believe that our focus on therapeutic protein and antibody drugs will be welcomed by the pharmaceutical industry and usher in a new paradigm of

rapid drug discovery and development that has the potential to dramatically improve productivity in our industry. Our company is prepared to share its know-how with others under the appropriate conditions. Ellen will play a central role in that process.'

## Clive Bennett joins Patheon

Clive V. Bennett has joined Patheon (Toronto, Canada) as Executive Vice-President of International Operations and will initially assume responsibility for the company's sites in Swindon (UK) and Bourgoin-Jallieu (France). Bennett's previous experience includes being Senior Vice-President of Operations and Head of Global Drug Product Supply at Hoechst Marion Roussel (now merged with Aventis Pharmaceuticals) until 1999. He joined Patheon's Management Advisory Board in January 2000 and has been providing the company with strategic counsel on current developments in the pharmaceutical industry.

## New Board of Directors and Executive Committee for BIO

The Biotechnology Industry Organization has released details of its Board of Directors and Executive Committee for 2001–2002. David E. Robinson (Ligand Pharmaceuticals, San Diego, CA, USA) has been voted in as Chairman; Hendrik Verfaillie (Monsanto Co., St Louis, MO, USA) will be Vice-Chairman for Food and Agriculture; Richard F. Pops (Alkermes, Cambridge, MA, USA) will be Vice-Chairman for Health Care; Thomas G. Wiggins (Connetics Corporation, Palo Alto, CA, USA) will be Secretary; Duane J. Roth (Alliance Pharmaceutical Corporation, San Diego) will be Treasurer; and Mark Skaletsky (The Althexis Co., Waltham, MA, USA) will be the Ex-Officio former Chairman.

Meanwhile, new members of the board for this year include Nancy T. Chang (Tanox, Houston, TX, USA), Charles A. Fischer (Dow AgroSciences, Indianapolis, IN, USA), Donal J. Geaney (Elan Corporation, Dublin, Ireland), William A. Haseltine (Human Genome Sciences, Rockville, MD, USA), Walter H. Moos (Mitokor, San Diego), James Mullen (Biogen, Cambridge, MA, USA), Edwin C. Quattlebaum (MetaMorphix, Baltimore,

MD, USA) and Edward T. Shonsey (Syngenta Seeds, Golden Valley, MN, USA).

## New Senior VP, Research for Hyseq

Hyseq (Sunnyvale, CA, USA) has appointed William F. Bennett to the position of Senior Vice-President of Research. Bennett has 20 years of experience in drug development gained in positions such as Senior Vice-President of Research and Manufacturing at Sensus Drug Development Corporation, Senior Vice-President Product Development at BigBearBio and Vice-President Research at COR Therapeutics. He has also worked in the R&D department at Genentech for 13 years in a variety of positions including as development project team leader of the TNKase project.

## Senior management changes at Variagenics

Variagenics (Cambridge, MA, USA) has announced three changes to its senior management positions. Edward E. Koval, who was previously Senior Director of Business Development, has been promoted to Vice-President of Corporate and Strategic Development. Meanwhile, R. Mark Adams has been promoted to Vice-President of Bioinformatics, from being Senior Director. Finally, James E. Aswell, previously Senior Project Manager at Bayer Diagnostics, has joined Variagenics in the newly created position of Senior Director of Diagnostics.

Koval has been at Variagenics since February 2000, after joining the company from being an independent business consultant to companies such as Chiron Corporation and Pharmacopeia. He has also been Director of Corporate Development at Chiron Corporation and Director of Corporate Planning and Development at Merck & Co. Meanwhile, Adams has been at Variagenics for the past three years. He was previously Director of Bioinformatics at AlphaGene and has served as a consultant to Incyte Pharmaceuticals. Finally, Aswell has over 20 years of experience in clinical diagnostics, biotechnology and scientific management. Before joining Bayer in 1991, he was a Research Manager at GeneTrak Systems and Serono Diagnostics.

People was written by  
*Rebecca N. Lawrence*